Oxford BioTherapeutics, Boehringer Ingelheim Extend Drug Discovery Collaboration
The firms have previously advanced two programs identified by Oxford's platform into Phase I clinical development.
Foundation Medicine, Boehringer Ingelheim Collaborate on CDx for Biliary Tract Cancer Drug
The companies will develop the FoundationOne CDx test as a companion diagnostic for Boehringer Ingelheim's BI 907828 in the US, Japan, and EU.
Illumina Touts New Partnerships, Sequencing Technology at JP Morgan Healthcare Conference
The company saw strong uptake of its sequencing platforms in the clinical oncology market, a trend that is projected to continue in 2022.
Notable Labs Licenses Blood Cancer Drug Volasertib from Oncoheroes, Plans Clinical Trials
The firm will use its predictive platform to identify the best patient populations to evaluate in clinical trials of volasertib.
Roche EGFR Mutation Test Approved by FDA as Companion Diagnostic for NSCLC
Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.